Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. [electronic resource]
Producer: 20180928Description: 535-538 p. digitalISSN:- 1998-4774
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Bevacizumab -- administration & dosage
- Biosimilar Pharmaceuticals -- administration & dosage
- Camptothecin -- administration & dosage
- Capecitabine -- administration & dosage
- Colorectal Neoplasms -- drug therapy
- Disease-Free Survival
- Drug-Related Side Effects and Adverse Reactions -- epidemiology
- Female
- Fluorouracil -- administration & dosage
- Humans
- India -- epidemiology
- Irinotecan
- Male
- Middle Aged
- Neoplasm Metastasis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.